The US Food and Drug Administration (FDA) has granted 510(k) clearance to Pathway Medical Technologies’ JETSTREAM G3 SF (Small Fixed) 1.6 mm revascularization catheter for the treatment of peripheral vascular disease (PVD).
JETSTREAM consists of a sterile, single-use catheter and control pod and a reusable, compact console that mounts to a standard I.V. stand.
The JETSTREAM G3 SF family of products is designed for enhanced performance in tortuousity (curves) and better navigation of the device through smaller arteries in the lower leg.
JETSTREAM G3 SF, optimized for treating blockages in arteries below the knee (BTK), clears blockages in the peripheral vasculature, restores blood flow and effectively treats PVD.
The addition of the 1.6 mm catheter to the JETSTREAM G3 SF family of products provides physicians with a broader array of treatment options for patients in need of BTK therapy, including the greater number of patients suffering from critical limb ischemia (CLI) and diabetes.